These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
355 related articles for article (PubMed ID: 21750205)
1. Early tumor progression associated with enhanced EGFR signaling with bortezomib, cetuximab, and radiotherapy for head and neck cancer. Argiris A; Duffy AG; Kummar S; Simone NL; Arai Y; Kim SW; Rudy SF; Kannabiran VR; Yang X; Jang M; Chen Z; Suksta N; Cooley-Zgela T; Ramanand SG; Ahsan A; Nyati MK; Wright JJ; Van Waes C Clin Cancer Res; 2011 Sep; 17(17):5755-64. PubMed ID: 21750205 [TBL] [Abstract][Full Text] [Related]
2. Phase I study of weekly nab-paclitaxel + weekly cetuximab + intensity-modulated radiation therapy (IMRT) in patients with stage III-IVB head and neck squamous cell carcinoma (HNSCC). Fury MG; Sherman EJ; Rao SS; Wolden S; Smith-Marrone S; Mueller B; Ng KK; Dutta PR; Gelblum DY; Lee JL; Shen R; Kurz S; Katabi N; Haque S; Lee NY; Pfister DG Ann Oncol; 2014 Mar; 25(3):689-694. PubMed ID: 24496920 [TBL] [Abstract][Full Text] [Related]
3. Phase II study of cetuximab in combination with cisplatin and radiation in unresectable, locally advanced head and neck squamous cell carcinoma: Eastern cooperative oncology group trial E3303. Egloff AM; Lee JW; Langer CJ; Quon H; Vaezi A; Grandis JR; Seethala RR; Wang L; Shin DM; Argiris A; Yang D; Mehra R; Ridge JA; Patel UA; Burtness BA; Forastiere AA Clin Cancer Res; 2014 Oct; 20(19):5041-51. PubMed ID: 25107914 [TBL] [Abstract][Full Text] [Related]
4. Phase I trial of dose-escalated cisplatin with concomitant cetuximab and hyperfractionated-accelerated radiotherapy in locally advanced squamous cell carcinoma of the head and neck. Kuhnt T; Sandner A; Wendt T; Engenhart-Cabillic R; Lammering G; Flentje M; Grabenbauer G; Schreiber A; Pirnasch A; Dunst J Ann Oncol; 2010 Nov; 21(11):2284-2289. PubMed ID: 20427347 [TBL] [Abstract][Full Text] [Related]
5. Cetuximab therapy in head and neck cancer: immune modulation with interleukin-12 and other natural killer cell-activating cytokines. Luedke E; Jaime-Ramirez AC; Bhave N; Roda J; Choudhary MM; Kumar B; Teknos TN; Carson WE Surgery; 2012 Sep; 152(3):431-40. PubMed ID: 22770960 [TBL] [Abstract][Full Text] [Related]
6. Cisplatin, 5-fluorouracil, and cetuximab (PFE) with or without cilengitide in recurrent/metastatic squamous cell carcinoma of the head and neck: results of the randomized phase I/II ADVANTAGE trial (phase II part). Vermorken JB; Peyrade F; Krauss J; Mesía R; Remenar E; Gauler TC; Keilholz U; Delord JP; Schafhausen P; Erfán J; Brümmendorf TH; Iglesias L; Bethe U; Hicking C; Clement PM Ann Oncol; 2014 Mar; 25(3):682-688. PubMed ID: 24567516 [TBL] [Abstract][Full Text] [Related]
7. Expression of amphiregulin and EGFRvIII affect outcome of patients with squamous cell carcinoma of the head and neck receiving cetuximab-docetaxel treatment. Tinhofer I; Klinghammer K; Weichert W; Knödler M; Stenzinger A; Gauler T; Budach V; Keilholz U Clin Cancer Res; 2011 Aug; 17(15):5197-204. PubMed ID: 21653686 [TBL] [Abstract][Full Text] [Related]
8. Inhibition of nuclear factor-kappaB and target genes during combined therapy with proteasome inhibitor bortezomib and reirradiation in patients with recurrent head-and-neck squamous cell carcinoma. Van Waes C; Chang AA; Lebowitz PF; Druzgal CH; Chen Z; Elsayed YA; Sunwoo JB; Rudy SF; Morris JC; Mitchell JB; Camphausen K; Gius D; Adams J; Sausville EA; Conley BA Int J Radiat Oncol Biol Phys; 2005 Dec; 63(5):1400-12. PubMed ID: 16005577 [TBL] [Abstract][Full Text] [Related]
9. Consensus guidelines for the management of radiation dermatitis and coexisting acne-like rash in patients receiving radiotherapy plus EGFR inhibitors for the treatment of squamous cell carcinoma of the head and neck. Bernier J; Bonner J; Vermorken JB; Bensadoun RJ; Dummer R; Giralt J; Kornek G; Hartley A; Mesia R; Robert C; Segaert S; Ang KK Ann Oncol; 2008 Jan; 19(1):142-9. PubMed ID: 17785763 [TBL] [Abstract][Full Text] [Related]
10. Induction chemotherapy with docetaxel, cisplatin and 5-fluorouracil followed by radiotherapy with cetuximab for locally advanced squamous cell carcinoma of the head and neck. Keil F; Selzer E; Berghold A; Reinisch S; Kapp KS; De Vries A; Greil R; Bachtiary B; Tinchon C; Anderhuber W; Burian M; Kasparek AK; Elsäßer W; Kainz H; Riedl R; Kopp M; Kornek G Eur J Cancer; 2013 Jan; 49(2):352-9. PubMed ID: 22981499 [TBL] [Abstract][Full Text] [Related]
11. Monitoring of circulating tumor cells and their expression of EGFR/phospho-EGFR during combined radiotherapy regimens in locally advanced squamous cell carcinoma of the head and neck. Tinhofer I; Hristozova T; Stromberger C; Keilhoiz U; Budach V Int J Radiat Oncol Biol Phys; 2012 Aug; 83(5):e685-90. PubMed ID: 22583603 [TBL] [Abstract][Full Text] [Related]
12. Cetuximab: a review of its use in squamous cell carcinoma of the head and neck. Frampton JE Drugs; 2010 Oct; 70(15):1987-2010. PubMed ID: 20883055 [TBL] [Abstract][Full Text] [Related]
13. Phase 1 and pharmacokinetic study of everolimus in combination with cetuximab and carboplatin for recurrent/metastatic squamous cell carcinoma of the head and neck. Saba NF; Hurwitz SJ; Magliocca K; Kim S; Owonikoko TK; Harvey D; Ramalingam SS; Chen Z; Rogerio J; Mendel J; Kono SA; Lewis C; Chen AY; Higgins K; El-Deiry M; Wadsworth T; Beitler JJ; Shin DM; Sun SY; Khuri FR Cancer; 2014 Dec; 120(24):3940-51. PubMed ID: 25103371 [TBL] [Abstract][Full Text] [Related]
14. Phase II study evaluating the addition of cetuximab to the concurrent delivery of weekly carboplatin, paclitaxel, and daily radiotherapy for patients with locally advanced squamous cell carcinomas of the head and neck. Suntharalingam M; Kwok Y; Goloubeva O; Parekh A; Taylor R; Wolf J; Zimrin A; Strome S; Ord R; Cullen KJ Int J Radiat Oncol Biol Phys; 2012 Apr; 82(5):1845-50. PubMed ID: 21601372 [TBL] [Abstract][Full Text] [Related]
15. Concurrent cetuximab, cisplatin, and concomitant boost radiotherapy for locoregionally advanced, squamous cell head and neck cancer: a pilot phase II study of a new combined-modality paradigm. Pfister DG; Su YB; Kraus DH; Wolden SL; Lis E; Aliff TB; Zahalsky AJ; Lake S; Needle MN; Shaha AR; Shah JP; Zelefsky MJ J Clin Oncol; 2006 Mar; 24(7):1072-8. PubMed ID: 16505426 [TBL] [Abstract][Full Text] [Related]
16. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. Bonner JA; Harari PM; Giralt J; Azarnia N; Shin DM; Cohen RB; Jones CU; Sur R; Raben D; Jassem J; Ove R; Kies MS; Baselga J; Youssoufian H; Amellal N; Rowinsky EK; Ang KK N Engl J Med; 2006 Feb; 354(6):567-78. PubMed ID: 16467544 [TBL] [Abstract][Full Text] [Related]
17. Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: an Eastern Cooperative Oncology Group study. Burtness B; Goldwasser MA; Flood W; Mattar B; Forastiere AA; J Clin Oncol; 2005 Dec; 23(34):8646-54. PubMed ID: 16314626 [TBL] [Abstract][Full Text] [Related]
18. Phase II study of the combination of cetuximab and weekly paclitaxel in the first-line treatment of patients with recurrent and/or metastatic squamous cell carcinoma of head and neck. Hitt R; Irigoyen A; Cortes-Funes H; Grau JJ; García-Sáenz JA; Cruz-Hernandez JJ; Ann Oncol; 2012 Apr; 23(4):1016-22. PubMed ID: 21865152 [TBL] [Abstract][Full Text] [Related]
19. Management of radiation dermatitis in patients receiving cetuximab and radiotherapy for locally advanced squamous cell carcinoma of the head and neck: proposals for a revised grading system and consensus management guidelines. Bernier J; Russi EG; Homey B; Merlano MC; Mesía R; Peyrade F; Budach W Ann Oncol; 2011 Oct; 22(10):2191-200. PubMed ID: 21606209 [TBL] [Abstract][Full Text] [Related]
20. Induction chemotherapy with docetaxel, cisplatin and capecitabine, followed by combined cetuximab and radiotherapy in patients with locally advanced inoperable squamous cell carcinoma of the head and neck: a phase I-II study. Perri F; Muto P; Argenone A; Ionna F; Longo F; Fulciniti F; Sandomenico F; Daponte A; Caponigro F Oncology; 2013; 84(4):251-4. PubMed ID: 23428719 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]